mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion
Claudia Gentile, William W. Feng, Sean M. Lenahan, Alexander Wang Ying, Daren C. Card, Florence T.H. Wu, Nhu‐An Pham, Nikolina Radulovich, Pinjiang Mary Cao, K. Hueniken, Quan Li, Ming‐Sound Tsao, JOSEPH S. KULESZA, Madeline M. Hinkley, Lishu Liao, , Cigall Kadoch
This study shows that inhibiting mSWI/SNF complexes enhances the effectiveness of KRAS inhibitors in lung cancers by reversing epithelial-mesenchymal transition resistance.
bioRxiv · Mar 1, 2026 · PreprintCancer Biology